Keyword: Tecentriq

While a Keytruda-chemo combo showed significant improvement in cutting disease worsening or death in SCLC, it didn't extend patients' lives.

Patients with small cell lung cancer don’t have a lot of options. But that fact didn’t convince NICE to foot the bill for Roche's Tecentriq.

Roche has faced criticism that the diagnostic used to ID trial patients might have swayed Tecentriq's lung cancer results. Not so, an analysis says.

Roche’s Tecentriq and Cotellic pairing went 0 for 1 in phase 3 melanoma trials—but Friday, they reversed that trend in a Zelboraf combo test.

Merck and Roche are no strangers to sparring with their I-O meds Keytruda and Tecentriq, but in TNBC, Keytruda's latest data take the prize.

The Tecentriq-chemo approval is the second one for the Roche PD-L1 drug in front-line NSCLC, following an OK for a regimen that also contains Avastin.

With the priority review, Imfinzi is now looking at a decision for use in frontline small cell lung cancer by the first quarter of 2020.

With a big head-to-head survival win, Roche is coming after Bayer's standard-of-care Nexavar in front-line liver cancer.

Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.

Combined with Avastin, Roche's IO med beat Bayer's standard-of-care Nexavar at stalling liver cancer progression—and helped patients live longer, too.